newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

  • Bezuclastinib demonstrated a 57% objective response rate per mIWG criteria & 80% per PPR criteria in AdvSM patients during the APEX Part 2 trial
  • 89% of patients achieved ≥50% reduction in bone marrow mast cells or clearance of aggregates
  • The drug showed a favorable safety profile with only 14.8% of patients requiring dose reductions & zero discontinuations due to treatment-related adverse events
  • Cogent Biosciences expects to submit a new drug application to the FDA for bezuclastinib in the first half of 2026
  • Detailed APEX trial data will be presented at a scientific meeting in the first half of 2026
  • Cogent announced inducement equity grants totaling 294,600 stock options & 34,000 restricted stock units to 13 new employees in December 2025
  • An investor conference call & webcast regarding the trial results was hosted on December 8, 2025
  • This marks the third positive pivotal trial result for bezuclastinib in 2025 following the SUMMIT & PEAK trials
  • Cogent plans for multiple commercial launches of bezuclastinib in the second half of 2026